Doctor of Osteopathy Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

William Corse

Diagnostic Radiology Doylestown, PA Doctor of Osteopathy

NPI 1730177452 CMS profile 305807

595 W State St, Doylestown, PA 18901

Open in the dashboard

General payments

$1,339,348

316 records reported · program years 2019–2025

Research payments

$590,122

Paid to them · 101 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$11,043 paid to institutions, not to them · program years 2024–2025

Through program year 2025, William Corse of Doylestown, PA is reported in the CMS Open Payments database as having received $1,339,348 across 316 general payments and $590,122 in research payments paid to them. Separately, studies naming them as principal investigator received $11,043 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 99th percentile of Diagnostic Radiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

14 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $60,095 14
2025 Research $145,283 23
2024 General $80,950 21
2024 Research $152,691 18
2023 General $83,350 14
2023 Research $207,483 24
2022 General $3,495 5
2022 Research $32,630 11
2021 General $702,009 112
2021 Research $33,401 17
2020 General $298,987 93
2020 Research $4,168 4
2019 General $110,463 57
2019 Research $14,468 4

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • William Corse
  • Diagnostic Radiology median
  • Middle half of Diagnostic Radiology
  • National median

In program year 2025, general payments to William Corse were reported at $60,095. Among 8,325 Diagnostic Radiology profiles paid that year, the median was $112 and the middle half received between $32 and $349.

Show as a table
Year William Corse Diagnostic Radiology median Middle half National median
2019 $110,463 $108 $29–$318 $163
2020 $298,987 $65 $21–$252 $114
2021 $702,009 $92 $24–$292 $132
2022 $3,495 $104 $29–$294 $149
2023 $83,350 $110 $29–$337 $160
2024 $80,950 $113 $30–$356 $164
2025 $60,095 $112 $32–$349 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Merck Sharp & Dohme Corporation $1,090,130 252 payments
  2. Pfizer Inc. $138,420 29 payments
  3. Boehringer Ingelheim Pharmaceuticals, Inc. $73,495 17 payments
  4. Genentech, Inc. $21,280 7 payments
  5. Boehringer Ingelheim International GmbH $13,350 2 payments
  6. Incyte Corporation $2,625 6 payments
  7. TESARO, Inc. $19 1 payment
  8. Lilly USA, LLC $16 1 payment
  9. Seattle Genetics, Inc. $14 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $1,339,300 313 payments
  2. Food and Beverage $49 3 payments
Products named General payments · program years 2019–2025
  1. KEYTRUDA $592,006 162 payments
  2. LENVIMA $479,024 84 payments
  3. Avastin $21,280 7 payments
  4. TECENTRIQ $21,280 7 payments
  5. Non-Covered Product $6,812 3 payments
  6. ZEJULA $19 1 payment
  7. ALIMTA $16 1 payment
  8. VERZENIO $16 1 payment
  9. CYRAMZA $16 1 payment
  10. ADCETRIS $14 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Regeneron Pharmaceuticals, Inc. $220,325 39 payments
  2. E.R. Squibb & Sons, L.L.C. $192,215 4 payments
  3. Boehringer Ingelheim Pharmaceuticals, Inc. $43,450 8 payments
  4. MorphoSys AG $42,339 27 payments
  5. Amgen Inc. $37,285 3 payments
  6. Genentech, Inc. $30,375 9 payments
  7. Takeda Pharmaceuticals U.S.A., Inc. $19,065 8 payments
  8. Boehringer Ingelheim International GmbH $3,145 1 payment
  9. Novo Nordisk AS $1,166 1 payment
  10. MorphoSys, US Inc. $758 1 payment

Records

417 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Diagnostic Radiology in Pennsylvania

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record